Richard K. Russell

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Sociodemographic Determinants of Hospitalized Exacerbations in Exposure-Defined COPD Phenotypes: A Nationwide Prospective Cohort Study in China.

Sociodemographic Determinants of Hospitalized Exacerbations in Exposure-Defined COPD Phenotypes: A Nationwide Prospective Cohort Study in China.

Journal: International journal of chronic obstructive pulmonary disease

Published: March 10, 2026

A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease.

A phase 2a, double-blind, randomised, placebo-controlled trial of the myeloperoxidase inhibitor, mitiperstat, in participants with chronic obstructive pulmonary disease.

Journal: The European respiratory journal

Published: November 28, 2025

Ensuring continued access to essential inhaled respiratory medications: a call to action from the Inhaled Respiratory medicine Innovation and environmental Sustainability (IRIS) group.

Ensuring continued access to essential inhaled respiratory medications: a call to action from the Inhaled Respiratory medicine Innovation and environmental Sustainability (IRIS) group.

Journal: The European respiratory journal

Published: September 09, 2025

Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report.

Blood Eosinophil Counts in Healthy Volunteers and in Patients with Asthma and COPD in India: A Multi-Centre Cross-Sectional Report.

Journal: International journal of chronic obstructive pulmonary disease

Published: June 20, 2025

Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO).

Phase 2a, Randomized Trial of Mitiperstat Versus Placebo in Patients with COPD at High Risk of Exacerbation (CRESCENDO).

Journal: International journal of chronic obstructive pulmonary disease

Published: March 20, 2025

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.

Journal: The Lancet. Respiratory medicine

Published: August 06, 2024

Results from a UK consensus about the optimal prescribing of medium strength triple therapy in uncontrolled adult asthma patients in the NHS.

Results from a UK consensus about the optimal prescribing of medium strength triple therapy in uncontrolled adult asthma patients in the NHS.

Journal: Journal of family medicine and primary care

Published: June 20, 2024

Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease.

Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease.

Journal: The Lancet. Respiratory medicine

Published: September 08, 2022

Renaming COPD exacerbations: the UK respiratory nursing perspective.

Renaming COPD exacerbations: the UK respiratory nursing perspective.

Journal: BMC pulmonary medicine

Published: March 26, 2021

Predicting treatment outcomes following an exacerbation of airways disease.

Predicting treatment outcomes following an exacerbation of airways disease.

Journal: PloS one

Published: November 18, 2020

Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD.

Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD.

Journal: The European respiratory journal

Published: December 16, 2019

Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.

Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.

Journal: Respiratory medicine

Published: March 21, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026